Terremoto Biosciences Raises $108M in Series C Financing Round

Why It Matters

The infusion of $108 million enables Terremoto to fast‑track covalent AKT inhibitors that could deliver more durable responses with fewer side effects, a critical need in oncology and rare‑disease therapy. It also signals sustained venture‑capital confidence in high‑risk, high‑reward cancer biotech ventures.

Key Takeaways

• $108M Series C funds AKT inhibitor pipeline.
• TER‑2013 in Phase 1 for genetically defined solid tumors.
• TER‑4480 to enter HHT clinic trials this year.
• Covalent technology aims for longer response, fewer side effects.
• Funding underscores $15B VC flow into cancer biotech.

Pulse Analysis

AKT has emerged as a pivotal node in cell‑growth signaling, making it a hot target for oncology drug developers. While AstraZeneca’s capivasertib secured FDA approval in 2023 and Roche’s ipatasertib faltered in Phase 3, the market still lacks an oral inhibitor that consistently balances potency with tolerability. This gap has spurred a wave of investment, as venture capitalists chase platforms that can overcome the pharmacokinetic and safety hurdles that have limited earlier candidates.

Terremoto’s strategy hinges on covalent binding technology, which creates a permanent link to the AKT enzyme, potentially extending drug exposure and reducing the dose needed for efficacy. Its lead asset, TER‑2013, is currently navigating a Phase 1 study in solid tumors bearing specific genetic mutations, while TER‑4480 targets hereditary hemorrhagic telangiectasia—a rare bleeding disorder with no approved treatments. By focusing on oral delivery and a covalent mechanism, Terremoto aims to differentiate its pipeline from existing AKT inhibitors, promising longer response durations and a cleaner side‑effect profile.

The $108 million raise reflects broader trends in life‑science financing, where investors are allocating larger sums to companies with clear mechanistic advantages and experienced leadership. Charles Baum’s track record at Mirati, culminating in a $4.8 billion acquisition, adds credibility that may attract further strategic partnerships or acquisition interest. As venture capital pours roughly $15 billion into cancer biotech annually, Terremoto is positioned to capitalize on both the scientific momentum around AKT inhibition and the financial appetite for innovative oncology solutions.

Deal Summary

San Francisco‑area biotech Terremoto Biosciences announced a $108 million Series C financing round. New investors RA Capital Management, Deep Track Capital, Osage University Partners and BeOne Medicines joined existing backers OrbiMed, Third Rock Ventures, Novo Holdings and Cormorant Asset Management. The capital will fund the development of AKT‑targeting therapies, including the Phase 1 candidate TER‑2013 and the upcoming HHT program TER‑4480.